ALIPAY
5.5.2024 16:30:26 CEST | Business Wire | Press release
Alipay's data indicates a significant uptick in both outbound and inbound tourism spending in China during the 2024 Labor Day holiday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240505795104/en/
The salesperson welcomes Chinese travelers to use Alipay for payment at Designer Outlet Roermond in the Netherlands (Photo: Business Wire)
Outbound Tourism
Transactions by Alipay users in overseas markets during the initial two days of the holiday saw a substantial 77% increase from the corresponding period in 2023, with total spending rising by 10% year-on-year.
For the 2024 Labor Day holiday, Alipay, an Alipay+ partner wallet, has joined hands with global merchants to launch extensive campaigns aimed at enticing Chinese tourists. Enabled by Alipay+, a suite of cross-border digital payment and digitalization technology solutions connecting global brands with mobile-savvy consumers worldwide, Chinese travelers can seamlessly pay for a wide array of services including shopping, dining, and entertainment at more than 8 million merchants across over 70 countries and regions. This convenience is all accessible through the familiar interface of their trusted Alipay app, eliminating the need to carry cash and the hassle of currency exchange.
Short-haul destinations across Asia continued to attract huge interest. Southeast Asia saw a 52% increase in spending by Alipay users year on year. Notably, Thailand emerged as the top destination in the region in terms of Alipay spending, while Malaysia showed the most impressive 171% year-on-year increase. In addition to these popular short-haul trips, Chinese travelers are increasingly using the extended five-day holiday to venture further afield. Long-haul destinations have gained traction, with North America, Europe, and Australia becoming the preferred choices for more exploratory and extended travels among Alipay users.
Specifically, Hong Kong SAR, Japan, Macao SAR, Korea, the United States, and Thailand stand out as top destinations for Chinese travelers, drawing the most Alipay users. In April, Alipay+ facilitated users of 14 leading overseas mobile wallets and bank apps from 9 countries and regions to make seamless payment in Hong Kong from their home apps, enhancing the travel experience and contributing to the region's tourism surge. Japan has risen to prominence as an enticing and budget-friendly destination for Chinese tourists, largely attributable to the yen's depreciation. This economic advantage has been reflected in a substantial surge in Alipay spending within the country, which saw an impressive year-on-year growth of 164%.
Traveling with a lighter carbon footprint has become a new fashion. Alipay has been adding more ways for its users to get around overseas, like ride-hailing and public transport. In Hong Kong, the number of transactions for public transport increased by 63% year-on-year.
Inbound Tourism
Over the Labor Day holiday, international travelers spent 700% more year-on-year using their international card-enabled Alipay accounts at merchants across the Chinese mainland. The number of visitors using Alipay for payment from the 15 countries1 benefiting from China's visa-free policy updates since mid-2023 increased by over 4 times compared to last year.
In April, Huangshan Tourism Group partnered with Alipay to launch “International Visitor Friendly Scenic Spot” ahead of the Labor Day holiday. The initiative helps global travelers visiting Huangshan enjoy convenient payment options, including card, mobile payment and cash, as well as claiming tailored digital red packets for shopping discounts and check travel guide and tips in 16 languages.
In addition to using Alipay, overseas consumers can also pay with their home e-wallets across China, enabled by Alipay+. Since September 2023, the Alipay+ solutions have supported 12 leading e-wallets and payment apps in Asia to serve their roaming users across Alipay’s 80-million-strong merchant network in China, including AlipayHK (Hong Kong SAR, China), Kaspi.kz (Kazakhstan), MPay (Macao SAR, China), Touch 'n Go eWallet (Malaysia), Hipay (Mongolia), NayaPay (Pakistan), Changi Pay (Singapore), OCBC Digital (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Toss Pay (South Korea), TrueMoney (Thailand).
About Alipay
In the digital era, Alipay has evolved from a trusted payment tool to an open platform that connects businesses, institutions, service providers, and other partners with consumers. Alipay enables partners from various industries to offer safe and convenient payment options. It also enables partners to communicate and deliver different digital services to their customers in China through Alipay mini programs, lifestyle accounts and other tools. The Alipay platform has connected over 80 million businesses with more than one billion consumers.
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalization technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
___________________________
1 The 15 countries include France, Germany, Italy, the Netherlands, Spain, Malaysia, Switzerland, Ireland, Hungary, Austria, Belgium, Luxembourg, Thailand, Singapore, and Brunei.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240505795104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
